Innate Pharma plans Phase 3 lacutamab trial, names new CMO
Go back to Innate Pharma plans Phase 3 lacutamab trial, names new CMO| Biophan Technologies, Inc. (AMEX: IPH) | Delayed: 0.04 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.04 | 52 Week High | $0.04 | |||
| Open | $0.04 | 52 Week Low | $0.04 | |||
| Day High | $0.04 | P/E | N/A | |||
| Day Low | $0.04 | EPS | $0.00 | |||
| Volume | 71,303 | |||||
| (NASDAQ: IPHA) | Delayed: 2.47 +0.32 (14.88%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.15 | 52 Week High | $ | |||
| Open | $2.50 | 52 Week Low | $ | |||
| Day High | $2.64 | P/E | N/A | |||
| Day Low | $2.44 | EPS | $ | |||
| Volume | 385,256 | |||||
